Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Serenity may feel hard to come by these days, but the natural world still offers solace for those willing to seek it.

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...

The recipient in Changsha, the capital of Hunan province, became the first man on the Chinese mainland to receive the HPV ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

A nutrient deficiency occurs when your body doesn’t get enough of a particular nutrient, whether that’s essential vitamins or ...